Credo Life Science
Posted on 27th January 2022
TOP-10 Pharmaceutical Pellets Manufacturers in India for Global Pharma Companies
Global pharma companies increasingly look to India for pellet manufacturing, drawn by cost efficiency, deep formulation expertise, and growing regulatory sophistication among the country’s top manufacturers.
Why India Attracts Global Buyers
Decades of generic manufacturing experience have built a large talent pool skilled in fluid-bed processing and coating technology, while many manufacturers now maintain DMF filings and WHO-GMP certification aligned with the toughest international standards.
What Global Companies Should Verify First
Before evaluating anything else, confirm WHO-GMP status, review specific DMF filings for target markets, and request documented evidence of completed bioequivalence studies on molecules of comparable complexity.
Technology Breadth Global Buyers Need
Manufacturers supporting the full spectrum — IR, SR, MR, EC, and ER pellets, plus taste-masked granules — let global companies consolidate diverse formulation needs under a single trusted partner rather than juggling multiple vendors.
Building a Reliable Long-Term Relationship
Global sourcing works best when treated as an ongoing partnership rather than a one-time transaction, with regular technical reviews, transparent communication, and clear quality agreements defining the relationship from the outset.
Practical Due Diligence Steps
Global buyers should request comparable product documentation, run an independent pilot batch before committing to volume, and confirm a manufacturer’s scale-up track record with concrete examples rather than general assurances. Cross-functional involvement from regulatory, quality, and supply chain teams tends to produce stronger sourcing decisions than procurement acting alone.
Credo Life Sciences: Built for Global Partnership
Credo Life Sciences, incorporated in 2014 in Hyderabad, reflects this model. The company’s WHO-GMP certified facilities and DMF-registered pellets meet USFDA, EU, and WHO-GMP standards across IR, SR, MR, EC, and ER platforms. Credo has completed pivotal bioequivalence studies on complex formulations and states a clear commitment to sharing technical documentation with global client companies throughout development and commercial manufacturing.
Conclusion: For global pharma companies, India’s leading manufacturers offer a compelling combination of cost, capability, and regulatory readiness — provided the right partner is chosen through disciplined evaluation.